Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

No matter how much she ate, she never felt satisfied. But after starting a non-FDA approved GLP-1 agonist—an injectable drug ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Originally intended as a treatment for diabetes, GLP-1 drugs like Ozempic could be set to turn the food and drink industry ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

The "Today" host underwent gastric bypass surgery in 2002 to help him lose weight.